000178305 001__ 178305
000178305 005__ 20240229133804.0
000178305 0247_ $$2doi$$a10.3390/cells10123489
000178305 0247_ $$2pmid$$apmid:34943994
000178305 0247_ $$2pmc$$apmc:PMC8700738
000178305 0247_ $$2altmetric$$aaltmetric:122850427
000178305 037__ $$aDKFZ-2021-03252
000178305 041__ $$aEnglish
000178305 082__ $$a570
000178305 1001_ $$aOstrovsky, Olga$$b0
000178305 245__ $$aCMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34+ Cell Mobilization.
000178305 260__ $$aBasel$$bMDPI$$c2021
000178305 3367_ $$2DRIVER$$aarticle
000178305 3367_ $$2DataCite$$aOutput Types/Journal article
000178305 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1641066220_6953
000178305 3367_ $$2BibTeX$$aARTICLE
000178305 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178305 3367_ $$00$$2EndNote$$aJournal Article
000178305 520__ $$aHeparanase is an endo-β-glucuronidase that is best known for its pro-cancerous effects but is also implicated in the pathogenesis of various viruses. Activation of heparanase is a common strategy to increase viral spread and trigger the subsequent inflammatory cascade. Using a Single Nucleotide Polymorphisms (SNP)-associated approach we identified enhancer and insulator regions that regulate HPSE expression. Although a role for heparanase in viral infection has been noticed, the impact of HPSE functional SNPs has not been determined. We investigated the effect of cytomegalovirus (CMV) serostatus on the involvement of HPSE enhancer and insulator functional SNPs in the risk of acute graft versus host disease (GVHD) and granulocyte-colony stimulating factor related CD34+ mobilization. A significant correlation between the C alleles of insulator rs4364254 and rs4426765 and CMV seropositivity was found in healthy donors and patients with hematological malignancies. The risk of developing acute GVHD after hematopoietic stem cell transplantation was identified only in CMV-seropositive patients. A significant correlation between the enhancer rs4693608 and insulator rs28649799 and CD34+ cell mobilization was demonstrated in the CMV-seropositive donors. It is thus conceivable that latent CMV infection modulates heparanase regulatory regions and enhances the effect of functional SNPs on heparanase function in normal and pathological processes.
000178305 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000178305 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178305 650_7 $$2Other$$aCMV
000178305 650_7 $$2Other$$aG-CSF-mobilization
000178305 650_7 $$2Other$$aHPSE gene
000178305 650_7 $$2Other$$aSNPs
000178305 650_7 $$2Other$$aacute GVHD
000178305 650_7 $$2Other$$aallogeneic HSCT
000178305 650_7 $$2Other$$aenhancer
000178305 650_7 $$2Other$$ainsulator
000178305 7001_ $$aBeider, Katia$$b1
000178305 7001_ $$aMorgulis, Yan$$b2
000178305 7001_ $$aBloom, Nira$$b3
000178305 7001_ $$0P:(DE-He78)a30064f6b2d9ab959d35315d7668c091$$aCid-Arregui, Angel$$b4$$udkfz
000178305 7001_ $$aShimoni, Avichai$$b5
000178305 7001_ $$aVlodavsky, Israel$$b6
000178305 7001_ $$00000-0002-0763-1265$$aNagler, Arnon$$b7
000178305 773__ $$0PERI:(DE-600)2661518-6$$a10.3390/cells10123489$$gVol. 10, no. 12, p. 3489 -$$n12$$p3489$$tCells$$v10$$x2073-4409$$y2021
000178305 909CO $$ooai:inrepo02.dkfz.de:178305$$pVDB
000178305 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a30064f6b2d9ab959d35315d7668c091$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000178305 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000178305 9141_ $$y2021
000178305 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELLS-BASEL : 2019$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-04
000178305 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000178305 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000178305 9201_ $$0I:(DE-He78)D122-20160331$$kD122$$lD122 AG Gezielte Tumorvakzine$$x0
000178305 980__ $$ajournal
000178305 980__ $$aVDB
000178305 980__ $$aI:(DE-He78)D122-20160331
000178305 980__ $$aUNRESTRICTED